News Releases
Investor Day Slated for
Revenues for the fourth fiscal quarter were
In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.
Operating income for the fourth fiscal quarter was
In the fourth fiscal quarter, the Company's diluted earnings per share
were
Reported gross profit for the fourth fiscal quarter was
Revenues for the
Fiscal Year 2013
Revenues for fiscal 2013 were
Reported diluted earnings per share for fiscal 2013 were
The Company continued its investment in Advertising and Promotion
(“A&P”) during fiscal 2013 in support of its core OTC brands. A&P for
the fiscal year was
Commentary
“We are very pleased with the excellent growth shown in revenue and
earnings per share for both the fourth quarter and fiscal year ended
“Our industry-leading and consistent cash flow from operations combined
with a strengthened balance sheet helped us de-lever substantially in
both the fourth quarter and for the fiscal year,” Mr. Mannelly
continued. “Our net debt was reduced by approximately
“Our strategies are in place and we are fully prepared to build on the success of fiscal 2013. As the largest independent OTC products company in the U.S., we are confident in our ability to continue to build brands, innovate within our portfolio, and invest appropriately for future value creation,” he said.
Free Cash Flow and Debt Reduction
The Company's record free cash flow (“FCF”) for the fourth fiscal
quarter ended
The Company's net debt at
Q4 Conference Call & Accompanying Slide Presentation
The Company will host a conference call to review its fourth quarter
results on
Investor Day is
The Company will host its first Investor Day on
About
The Company markets and distributes brand name over-the-counter and
household cleaning products throughout the U.S. and
Note Regarding Forward-Looking Statements
This news release contains "forward-looking statements" within the
meaning of the federal securities laws that are intended to qualify for
the Safe Harbor from liability established by the Private Securities
Litigation Reform Act of 1995. "Forward-looking statements" generally
can be identified by the use of forward-looking terminology such as
"assumptions," "target," "guidance," "outlook," "plans," "projection,"
"may," "will," "would," "expect," "intend," "estimate," "anticipate,"
"believe”, "potential," or "continue" (or the negative or other
derivatives of each of these terms) or similar terminology. The
"forward-looking statements" include, without limitation, statements
regarding our ability to build brands, innovate our product portfolio,
invest to create value, and our acquisition capacity. These statements
are based on management's estimates and assumptions with respect to
future events and financial performance and are believed to be
reasonable, though are inherently uncertain and difficult to predict.
Actual results could differ materially from those expected as a result
of a variety of factors, including the impact of our advertising and
promotional initiatives, competition in our industry, and the success of
our new product introductions and integration of newly acquired
products. A discussion of other factors that could cause results to vary
is included in the Company's Annual Report on Form 10-K for the year
ended
Prestige Brands Holdings, Inc. Consolidated Statements of Income and Comprehensive Income (Unaudited) |
|||||||||||||||||||||||||
Three Months Ended March 31, | Year Ended March 31, | ||||||||||||||||||||||||
(In thousands, except per share data) | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Revenues | |||||||||||||||||||||||||
Net sales | $ | 153,659 | $ | 133,160 | $ | 620,394 | $ | 437,838 | |||||||||||||||||
Other revenues | 854 | 836 | 3,203 | 3,247 | |||||||||||||||||||||
Total revenues | 154,513 | 133,996 | 623,597 | 441,085 | |||||||||||||||||||||
Cost of Sales | |||||||||||||||||||||||||
Cost of sales (exclusive of depreciation shown below) | 66,443 | 65,508 | 276,381 | 213,701 | |||||||||||||||||||||
Gross profit | 88,070 | 68,488 | 347,216 | 227,384 | |||||||||||||||||||||
Operating Expenses | |||||||||||||||||||||||||
Advertising and promotion | 23,259 | 18,547 | 90,630 | 57,127 | |||||||||||||||||||||
General and administrative | 11,353 | 24,334 | 51,467 | 56,700 | |||||||||||||||||||||
Depreciation and amortization | 3,285 | 3,051 | 13,235 | 10,734 | |||||||||||||||||||||
Total operating expenses | 37,897 | 45,932 | 155,332 | 124,561 | |||||||||||||||||||||
Operating income | 50,173 | 22,556 | 191,884 | 102,823 | |||||||||||||||||||||
Other (income) expense | |||||||||||||||||||||||||
Interest income | (4 | ) | (14 | ) | (13 | ) | (18 | ) | |||||||||||||||||
Interest expense | 18,242 | 16,361 | 84,420 | 41,338 | |||||||||||||||||||||
Gain on settlement | — | — | — | (5,063 | ) | ||||||||||||||||||||
Loss on extinguishment of debt | 1,443 | 5,409 | 1,443 | 5,409 | |||||||||||||||||||||
Total other expense | 19,681 | 21,756 | 85,850 | 41,666 | |||||||||||||||||||||
Income before income taxes | 30,492 | 800 | 106,034 | 61,157 | |||||||||||||||||||||
Provision for income taxes | 11,143 | 815 | 40,529 | 23,945 | |||||||||||||||||||||
Net income (loss) | $ | 19,349 | $ | (15 | ) | $ | 65,505 | $ | 37,212 | ||||||||||||||||
Earnings per share: | |||||||||||||||||||||||||
Basic | $ | 0.38 | $ | — | $ | 1.29 | $ | 0.74 | |||||||||||||||||
Diluted | $ | 0.37 | $ | — | $ | 1.27 | $ | 0.73 | |||||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||||||||
Basic | 51,147 | 50,314 | 50,633 | 50,270 | |||||||||||||||||||||
Diluted | 51,913 | 50,992 | 51,440 | 50,748 | |||||||||||||||||||||
Comprehensive income, net of tax: | |||||||||||||||||||||||||
Currency translation adjustments | (114 | ) | 57 | (91 | ) | (13 | ) | ||||||||||||||||||
Total other comprehensive income (loss) | (114 | ) | 57 | (91 | ) | (13 | ) | ||||||||||||||||||
Comprehensive income | $ | 19,235 | $ | 42 | $ | 65,414 | $ | 37,199 | |||||||||||||||||
Prestige Brands Holdings, Inc. Consolidated Balance Sheets (Unaudited) |
|||||||||||||
(In thousands)
Assets |
March 31, 2013 |
March 31, 2012 |
|||||||||||
Current assets | |||||||||||||
Cash and cash equivalents | $ | 15,670 | $ | 19,015 | |||||||||
Accounts receivable, net | 73,053 | 60,228 | |||||||||||
Inventories | 60,201 | 51,113 | |||||||||||
Deferred income tax assets | 6,349 | 5,283 | |||||||||||
Prepaid expenses and other current assets | 8,900 | 11,396 | |||||||||||
Total current assets | 164,173 | 147,035 | |||||||||||
Property and equipment, net | 9,896 | 1,304 | |||||||||||
Goodwill | 167,546 | 173,702 | |||||||||||
Intangible assets, net | 1,373,240 | 1,400,522 | |||||||||||
Other long-term assets | 24,944 | 35,713 | |||||||||||
Total Assets | $ | 1,739,799 | $ | 1,758,276 | |||||||||
Liabilities and Stockholders' Equity | |||||||||||||
Current liabilities | |||||||||||||
Accounts payable | $ | 51,376 | $ | 26,726 | |||||||||
Accrued interest payable | 13,894 | 13,889 | |||||||||||
Other accrued liabilities | 31,398 | 23,308 | |||||||||||
Total current liabilities | 96,668 | 63,923 | |||||||||||
Long-term debt | |||||||||||||
Principal amount | 978,000 | 1,135,000 | |||||||||||
Less unamortized discount | (7,100 | ) | (11,092 | ) | |||||||||
Long-term debt, net of unamortized discount | 970,900 | 1,123,908 | |||||||||||
Deferred income tax liabilities | 194,288 | 167,717 | |||||||||||
Total Liabilities | 1,261,856 | 1,355,548 | |||||||||||
Stockholders' Equity | |||||||||||||
Preferred stock - $0.01 par value | |||||||||||||
Authorized - 5,000 shares | |||||||||||||
Issued and outstanding - None | — | — | |||||||||||
Preferred share rights | 283 | 283 | |||||||||||
Common stock - $0.01 par value | |||||||||||||
Authorized - 250,000 shares | |||||||||||||
Issued - 51,311 shares and 50,466 shares at March 31, 2013 and 2012, respectively | 513 | 505 | |||||||||||
Additional paid-in capital | 401,691 | 391,898 | |||||||||||
Treasury stock, at cost - 181 shares at March 31, 2013 and March 31, 2012 | (687 | ) | (687 | ) | |||||||||
Accumulated other comprehensive loss, net of tax | (104 | ) | (13 | ) | |||||||||
Retained earnings | 76,247 | 10,742 | |||||||||||
Total Stockholders' Equity | 477,943 | 402,728 | |||||||||||
Total Liabilities and Stockholders' Equity | $ | 1,739,799 | $ | 1,758,276 | |||||||||
Prestige Brands Holdings, Inc. Consolidated Statements of Cash Flows (Unaudited) |
|||||||||||||
Year Ended March 31, | |||||||||||||
(In thousands) | 2013 | 2012 | |||||||||||
Operating Activities | |||||||||||||
Net income | $ | 65,505 | $ | 37,212 | |||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||||
Depreciation and amortization | 13,235 | 10,734 | |||||||||||
Deferred income taxes | 25,505 | 13,793 | |||||||||||
Amortization of deferred financing costs | 9,832 | 1,630 | |||||||||||
Stock-based compensation costs | 3,772 | 3,078 | |||||||||||
Loss on extinguishment of debt | 1,443 | 5,409 | |||||||||||
Amortization of debt discount | 4,632 | 1,030 | |||||||||||
Lease termination costs | 975 | — | |||||||||||
Loss on disposal of equipment | 103 | — | |||||||||||
Changes in operating assets and liabilities, net of effects of acquisitions | |||||||||||||
Accounts receivable | (12,882 | ) | (15,854 | ) | |||||||||
Inventories | (9,342 | ) | 3,710 | ||||||||||
Prepaid expenses and other current assets | 3,096 | (3,009 | ) | ||||||||||
Accounts payable | 24,677 | 5,127 | |||||||||||
Accrued liabilities | 7,054 | 4,592 | |||||||||||
Net cash provided by operating activities | 137,605 | 67,452 | |||||||||||
Investing Activities | |||||||||||||
Purchases of property and equipment | (10,268 | ) | (606 | ) | |||||||||
Proceeds from sale of property and equipment | 15 | — | |||||||||||
Proceeds from escrow of Blacksmith acquisition | — | 1,200 | |||||||||||
Proceeds from sale of Phazyme brand | 21,700 | — | |||||||||||
Acquisition of brands from GSK | — | (662,800 | ) | ||||||||||
Acquisition of brands from GSK purchase price adjustments | (226 | ) | — | ||||||||||
Net cash provided by (used in) investing activities | 11,221 | (662,206 | ) | ||||||||||
Financing Activities | |||||||||||||
Proceeds from issuance of Senior Notes | — | 250,000 | |||||||||||
Proceeds from issuance of 2012 Term Loan and 2010 Term Loan | — | 650,100 | |||||||||||
Repayment of 2010 Term Loan | — | (242,000 | ) | ||||||||||
Payment of deferred financing costs | (1,146 | ) | (33,284 | ) | |||||||||
Repayment of long-term debt | (190,000 | ) | (25,000 | ) | |||||||||
Repayments under revolving credit agreement | (15,000 | ) | — | ||||||||||
Borrowings under revolving credit agreement | 48,000 | — | |||||||||||
Proceeds from exercise of stock options | 6,029 | 889 | |||||||||||
Shares surrendered as payment of tax withholding | — | (271 | ) | ||||||||||
Net cash (used in) provided by financing activities | (152,117 | ) | 600,434 | ||||||||||
Effects of exchange rate changes on cash and cash equivalents | (54 | ) | 1 | ||||||||||
(Decrease) increase in cash and cash equivalents | (3,345 | ) | 5,681 | ||||||||||
Cash and cash equivalents - beginning of year | 19,015 | 13,334 | |||||||||||
Cash and cash equivalents - end of year | $ | 15,670 | $ | 19,015 | |||||||||
Interest paid | $ | 69,641 | $ | 34,977 | |||||||||
Income taxes paid | $ | 10,624 | $ | 12,865 | |||||||||
Prestige Brands Holdings, Inc. Consolidated Statements of Income Business Segments (Unaudited) |
||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, 2013 | Year Ended March 31, 2013 | |||||||||||||||||||||||||||||||||||
OTC |
Household |
Consolidated |
OTC |
Household |
Consolidated | |||||||||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||||||||||||||
Net sales | $ | 133,614 | $ | 20,045 | $ | 153,659 | $ | 536,247 | $ | 84,147 | $ | 620,394 | ||||||||||||||||||||||||
Other revenues | 164 | 690 | 854 | 684 | 2,519 | 3,203 | ||||||||||||||||||||||||||||||
Total revenues | 133,778 | 20,735 | 154,513 | 536,931 | 86,666 | 623,597 | ||||||||||||||||||||||||||||||
Cost of sales | 51,405 | 15,038 | 66,443 | 211,654 | 64,727 | 276,381 | ||||||||||||||||||||||||||||||
Gross profit | 82,373 | 5,697 | 88,070 | 325,277 | 21,939 | 347,216 | ||||||||||||||||||||||||||||||
Advertising and promotion | 22,228 | 1,031 | 23,259 | 84,537 | 6,093 | 90,630 | ||||||||||||||||||||||||||||||
Contribution margin | $ | 60,145 | $ | 4,666 | 64,811 | $ | 240,740 | $ | 15,846 | 256,586 | ||||||||||||||||||||||||||
Other operating expenses | 14,638 | 64,702 | ||||||||||||||||||||||||||||||||||
Operating income | 50,173 | 191,884 | ||||||||||||||||||||||||||||||||||
Other expense | 19,681 | 85,850 | ||||||||||||||||||||||||||||||||||
Income before income taxes | 30,492 | 106,034 | ||||||||||||||||||||||||||||||||||
Provision for income taxes | 11,143 | 40,529 | ||||||||||||||||||||||||||||||||||
Net income | $ | 19,349 | $ | 65,505 | ||||||||||||||||||||||||||||||||
Three Months Ended March 31, 2012 | Year Ended March 31, 2012 | |||||||||||||||||||||||||||||||||||
OTC |
Household |
Consolidated |
OTC |
Household |
Consolidated | |||||||||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||||||||||||||
Net sales | $ | 109,570 | $ | 23,590 | $ | 133,160 | $ | 344,282 | $ | 93,556 | $ | 437,838 | ||||||||||||||||||||||||
Other revenues | 167 | 669 | 836 | 719 | 2,528 | 3,247 | ||||||||||||||||||||||||||||||
Total revenues | 109,737 | 24,259 | 133,996 | 345,001 | 96,084 | 441,085 | ||||||||||||||||||||||||||||||
Cost of sales | 45,953 | 19,555 | 65,508 | 143,151 | 70,550 | 213,701 | ||||||||||||||||||||||||||||||
Gross profit | 63,784 | 4,704 | 68,488 | 201,850 | 25,534 | 227,384 | ||||||||||||||||||||||||||||||
Advertising and promotion | 17,149 | 1,398 | 18,547 | 51,895 | 5,232 | 57,127 | ||||||||||||||||||||||||||||||
Contribution margin | $ | 46,635 | $ | 3,306 | 49,941 | $ | 149,955 | $ | 20,302 | 170,257 | ||||||||||||||||||||||||||
Other operating expenses | 27,385 | 67,434 | ||||||||||||||||||||||||||||||||||
Operating income | 22,556 | 102,823 | ||||||||||||||||||||||||||||||||||
Other expense | 21,756 | 41,666 | ||||||||||||||||||||||||||||||||||
Income before income taxes | 800 | 61,157 | ||||||||||||||||||||||||||||||||||
Provision for income taxes | 815 | 23,945 | ||||||||||||||||||||||||||||||||||
Net income | $ | (15 | ) | $ | 37,212 | |||||||||||||||||||||||||||||||
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense (income), income taxes, depreciation and amortization, income or loss from discontinued operations or the sale thereof and Non-GAAP Adjusted EBITDA as earnings before interest expense (income), income taxes, depreciation and amortization, income or loss from discontinued operations and the sale thereof, gain on settlement, loss on extinguishment of debt, certain other legal and professional fees, and acquisition-related costs. We define Non-GAAP Adjusted Gross Margin as Gross Profit before certain acquisition and integration-related costs. We define Non-GAAP Adjusted Operating Income as Operating Income minus certain other legal and professional fees, acquisition and other integration costs. We define Non-GAAP Adjusted Net Income as Net Income before gain on settlement, loss on extinguishment of debt, certain other legal and professional fees, acquisition and integration-related costs, income or loss from discontinued operations and sale thereof, the applicable tax impacts associated with these items and the tax impacts of state tax rate adjustments and other non-deductible items. Non-GAAP Adjusted EPS is calculated based on Non-GAAP Adjusted Net Income, divided by the weighted average number of common and potential common shares outstanding during the period. We define Non-GAAP Free Cash Flow as Net Cash provided by operating activities less cash paid for capital expenditures. Non-GAAP Free Cash Flow per Share is calculated based on Non-GAAP Free Cash Flow, divided by the weighted average number of common and potential common shares outstanding during the period. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Operating Income, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow and Non-GAAP Free Cash Flow per Share may not be comparable to similarly titled measures reported by other companies.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Operating Income, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow and Non-GAAP Free Cash Flow per Share because they provide additional ways to view our operations, when considered with both our GAAP results and the reconciliation to net income and net cash provided by operating activities, respectively, which we believe provide a more complete understanding of our business than could be obtained absent this disclosure. Additionally, we believe that Free Cash Flow and Free Cash Flow per Share are commonly used measures of liquidity and are indicative of cash available for debt repayment and acquisitions. Each of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Operating Income, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow and Non-GAAP Free Cash Flow per Share is presented solely as a supplemental disclosure because (i) we believe it is a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing our ability to pursue acquisitions or to service or incur indebtedness; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Operating Income, Non-GAAP Adjusted Net Income and Non-GAAP Adjusted EPS internally to evaluate the performance of our personnel and also as a benchmark to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Operating Income, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow and Non-GAAP Free Cash Flow per Share has limitations, and you should not consider these measures in isolation from or as an alternative to GAAP measures such as Operating income, Net income, and Net cash flow provided by operating activities, or cash flow statement data prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The following tables set forth the reconciliation of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Operating Income, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow and Non-GAAP Free Cash Flow per Share, all of which are non-GAAP financial measures, to GAAP Gross Profit, GAAP Operating Income, GAAP Net Income, GAAP Diluted EPS and GAAP Net cash provided by operating activities, our most directly comparable financial measures presented in accordance with GAAP.
Reconciliation of GAAP Gross Margin to Non-GAAP Adjusted Gross Margin: |
|||||||||||||||||||||||||
Three Months Ended March 31, | Year Ended March 31, | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||
GAAP Total Revenues | $ | 154,513 | $ | 133,996 | $ | 623,597 | $ | 441,085 | |||||||||||||||||
Adjustments: |
|||||||||||||||||||||||||
Additional slotting costs associated with GSK | — | — | 411 | — | |||||||||||||||||||||
Total adjustments | — | — | 411 | — | |||||||||||||||||||||
Non-GAAP Adjusted Total Revenues | $ | 154,513 | $ | 133,996 | $ | 624,008 | $ | 441,085 | |||||||||||||||||
GAAP Gross Profit | $ | 88,070 | $ | 68,488 | $ | 347,216 | $ | 227,384 | |||||||||||||||||
Adjustments: |
|||||||||||||||||||||||||
Additional slotting costs associated with GSK | — | — | 411 | — | |||||||||||||||||||||
Inventory step-up charge associated with acquisitions | — | 1,795 | 23 | 1,795 | |||||||||||||||||||||
Additional product testing costs associated with GSK | — | — | 220 | — | |||||||||||||||||||||
Additional supplier transition costs associated with GSK | — | — | 5,426 | — | |||||||||||||||||||||
Total adjustments | — | 1,795 | 6,080 | 1,795 | |||||||||||||||||||||
Non-GAAP Adjusted Gross Margin | $ | 88,070 | $ | 70,283 | $ | 353,296 | $ | 229,179 | |||||||||||||||||
Non-GAAP Adjusted Gross Margin % | 57.0 | % | 52.5 | % | 56.6 | % | 52.0 | % | |||||||||||||||||
Reconciliation of GAAP Operating Income to Non-GAAP Adjusted Operating Income: |
||||||||||||||||||||||||
Three Months Ended March 31, | Year Ended March 31, | |||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
GAAP Operating Income | $ | 50,173 | $ | 22,556 | $ | 191,884 | $ | 102,823 | ||||||||||||||||
Adjustments: |
||||||||||||||||||||||||
Additional slotting costs associated with GSK | — | — | 411 | — | ||||||||||||||||||||
Inventory step-up charge associated with acquisitions | — | 1,795 | 23 | 1,795 | ||||||||||||||||||||
Additional product testing costs associated with GSK | — | — | 220 | — | ||||||||||||||||||||
Additional supplier transition costs associated with GSK | — | — | 5,426 | — | ||||||||||||||||||||
Legal and professional fees associated with acquisitions | — | 8,142 | 98 | 13,807 | ||||||||||||||||||||
Unsolicited proposal costs | — | 1,737 | 534 | 1,737 | ||||||||||||||||||||
Transition and integration costs associated with GSK | — | 3,588 | 5,811 | 3,588 | ||||||||||||||||||||
Total adjustments | — | 15,262 | 12,523 | 20,927 | ||||||||||||||||||||
Non-GAAP Adjusted Operating Income | $ | 50,173 | $ | 37,818 | $ | 204,407 | $ | 123,750 | ||||||||||||||||
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA: |
|||||||||||||||||||||||||
Three Months Ended March 31, | Year Ended March 31, | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||
GAAP Net Income | $ | 19,349 | $ | (15 | ) | $ | 65,505 | $ | 37,212 | ||||||||||||||||
Interest expense, net | 18,238 | 16,347 | 84,407 | 41,320 | |||||||||||||||||||||
Income tax provision | 11,143 | 815 | 40,529 | 23,945 | |||||||||||||||||||||
Depreciation and amortization | 3,285 | 3,051 | 13,235 | 10,734 | |||||||||||||||||||||
Non-GAAP EBITDA: | 52,015 | 20,198 | 203,676 | 113,211 | |||||||||||||||||||||
Adjustments: |
|||||||||||||||||||||||||
Gain on settlement | — | — | — | (5,063 | ) | ||||||||||||||||||||
Loss on extinguishment of debt | 1,443 | 5,409 | 1,443 | 5,409 | |||||||||||||||||||||
Additional slotting costs associated with GSK | — | — | 411 | — | |||||||||||||||||||||
Inventory step-up charge associated with acquisitions | — | 1,795 | 23 | 1,795 | |||||||||||||||||||||
Additional product testing costs associated with GSK | — | — | 220 | — | |||||||||||||||||||||
Additional supplier transition costs associated with GSK | — | — | 5,426 | — | |||||||||||||||||||||
Legal and professional fees associated with acquisitions | — | 8,142 | 98 | 13,807 | |||||||||||||||||||||
Unsolicited proposal costs | — | 1,737 | 534 | 1,737 | |||||||||||||||||||||
Transition and integration costs associated with GSK | — | 3,588 | 5,811 | 3,588 | |||||||||||||||||||||
Total adjustments | 1,443 | 20,671 | 13,966 | 21,273 | |||||||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 53,458 | $ | 40,869 | $ | 217,642 | $ | 134,484 | |||||||||||||||||
Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and related Adjusted Earnings Per Share: |
||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | Year Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||
2013 |
2013 |
2012 |
2012 |
2013 |
2013 |
2012 |
2012 |
|||||||||||||||||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||||||||||||||||||||||||
GAAP Net Income | $ | 19,349 | $ | 0.37 | $ | (15 | ) | $ | — | $ | 65,505 | $ | 1.27 | $ | 37,212 | $ | 0.73 | |||||||||||||||||||||||||||||
Adjustments: |
||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement | — | — | — | — | — | — | (5,063 | ) | (0.10 | ) | ||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | 1,443 | 0.03 | 5,409 | 0.11 | 1,443 | 0.03 | 5,409 | 0.11 | ||||||||||||||||||||||||||||||||||||||
Additional slotting costs associated with GSK | — | — | — | — | 411 | 0.01 | — | — | ||||||||||||||||||||||||||||||||||||||
Inventory step-up charge associated with acquisitions | — | — | 1,795 | 0.04 | 23 | — | 1,795 | 0.04 | ||||||||||||||||||||||||||||||||||||||
Additional product testing costs associated with GSK | — | — | — | — | 220 | — | — | — | ||||||||||||||||||||||||||||||||||||||
Additional supplier transition costs associated with GSK | — | — | — | — | 5,426 | 0.11 | — | — | ||||||||||||||||||||||||||||||||||||||
Legal and professional fees associated with acquisitions | — | — | 8,142 | 0.16 | 98 | — |
|
13,807 | 0.27 | |||||||||||||||||||||||||||||||||||||
Unsolicited proposal costs | — | — | 1,737 | 0.03 | 534 | 0.01 | 1,737 | 0.03 | ||||||||||||||||||||||||||||||||||||||
Transition and integration costs associated with GSK | — | — | 3,588 | 0.07 | 5,811 | 0.11 | 3,588 | 0.07 | ||||||||||||||||||||||||||||||||||||||
Accelerated amortization of debt discount and issue costs | — | — | — | — | 7,746 | 0.15 | — | — | ||||||||||||||||||||||||||||||||||||||
Tax impact of adjustments | (409 | ) | (0.01 | ) | (7,816 | ) | (0.15 | ) | (8,329 | ) | (0.16 | ) | (8,091 | ) | (0.16 | ) | ||||||||||||||||||||||||||||||
Tax impact of state rate adjustments and other non-deductible items | (1,741 | ) | (0.03 | ) | — | — | (1,741 | ) | (0.03 | ) | (237 | ) | — | |||||||||||||||||||||||||||||||||
Total adjustments | (707 | ) | (0.01 | ) | 12,855 | 0.26 | 11,642 | 0.23 | 12,945 | 0.26 | ||||||||||||||||||||||||||||||||||||
Non-GAAP Adjusted Net Income and Adjusted EPS | $ | 18,642 | $ | 0.36 | $ | 12,840 | $ | 0.26 | $ | 77,147 | $ | 1.50 | $ | 50,157 | $ | 0.99 | ||||||||||||||||||||||||||||||
Reconciliation of GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow: |
|||||||||||||||||||||||||
Three Months Ended March 31, | Year Ended March 31, | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||
GAAP Net cash provided by operating activities | $ | 36,729 | $ | 19,459 | $ | 137,605 | $ | 67,452 | |||||||||||||||||
Additions to property and equipment for cash | (1,346 | ) | (248 | ) | (10,268 | ) | (606 | ) | |||||||||||||||||
Non-GAAP Free Cash Flow | $ | 35,383 | $ | 19,211 | $ | 127,337 | $ | 66,846 | |||||||||||||||||
Non-GAAP Free Cash Flow per Share | $ | 0.68 | $ | 0.38 | $ | 2.48 | $ | 1.32 | |||||||||||||||||
Reconciliation of GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow and Non-GAAP Free Cash Flow per Share: |
|||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | Year Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||||
2013 |
2013 Free |
2012 |
2012 Free |
2013 |
2013 Free |
2012 |
2012 Free |
||||||||||||||||||||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||||||||||||||||||||||
GAAP Net Income | $ | 19,349 | $ | 0.37 | $ | (15 | ) | $ | — | $ | 65,505 | $ | 1.27 | $ | 37,212 | $ | 0.73 | ||||||||||||||||||||||||||||
Adjustments: |
|||||||||||||||||||||||||||||||||||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows | 17,465 | 0.34 | 16,776 | 0.33 | 59,497 | 1.16 | 35,674 | 0.71 | |||||||||||||||||||||||||||||||||||||
Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows | (85 | ) | — | 2,698 | 0.05 | 12,603 | 0.25 | (5,434 | ) | (0.11 | ) | ||||||||||||||||||||||||||||||||||
Total adjustments | 17,380 | 0.34 | 19,474 | 0.38 | 72,100 | 1.41 | 30,240 | 0.60 | |||||||||||||||||||||||||||||||||||||
GAAP Net cash provided by operating activities | $ | 36,729 | $ | 0.71 | $ | 19,459 | $ | 0.38 | $ | 137,605 | $ | 2.68 | $ | 67,452 | $ | 1.33 | |||||||||||||||||||||||||||||
Additions to property and equipment for cash | $ | (1,346 | ) | $ | (0.03 | ) | $ | (248 | ) | $ | — | $ | (10,268 | ) | $ | (0.20 | ) | $ | (606 | ) | $ | (0.01 | ) | ||||||||||||||||||||||
Non-GAAP Free Cash Flow per Share | $ | 35,383 | $ | 0.68 | $ | 19,211 | $ | 0.38 | $ | 127,337 | $ | 2.48 | $ | 66,846 | $ | 1.32 | |||||||||||||||||||||||||||||
Source:
Prestige Brands Holdings, Inc.
Dean Siegal, 914-524-6819